Potential Barriers of Patient Involvement in Health Technology Assessment in Central and Eastern European Countries

被引:6
作者
Dimitrova, Maria [1 ]
Jakab, Ivett [2 ]
Mitkova, Zornitsa [1 ]
Kamusheva, Maria [1 ]
Tachkov, Konstantin [1 ]
Nemeth, Bertalan [2 ]
Zemplenyi, Antal [2 ,3 ]
Dawoud, Dalia [4 ,5 ]
Delnoij, Diana M. J. [6 ,7 ]
Houyez, Francois [8 ]
Kalo, Zoltan [2 ,9 ]
机构
[1] Med Univ Sofia, Fac Pharm, Sofia, Bulgaria
[2] Syreon Res Inst, Budapest, Hungary
[3] Univ Pecs, Fac Pharm, Ctr Hlth Technol Assessment & Pharmacoecon Res, Pecs, Hungary
[4] Natl Inst Hlth & Care Excellence, London, England
[5] Cairo Univ, Fac Pharm, Cairo, Egypt
[6] Erasmus Univ, Erasmus Sch Hlth Policy & Management, Rotterdam, Netherlands
[7] Natl Hlth Care Inst Zorginst Nederland, Diemen, Netherlands
[8] EURORDIS Eurordis European Org Rare Dis, Paris, France
[9] Semmelweis Univ, Ctr Hlth Technol Assessment, Budapest, Hungary
基金
欧盟地平线“2020”;
关键词
patient engagement; health technology assessment (HTA); barrier; central and eastern EU countries; potential; DISCRETE-CHOICE EXPERIMENTS; PATIENTS PERSPECTIVES; PUBLIC ENGAGEMENT; ORGANIZATIONS; PARTICIPATION; FRAMEWORK; DESIGN; VIEWS;
D O I
10.3389/fpubh.2022.922708
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Patients' perspectives are important to identify preferences, estimate values and appreciate unmet medical needs in the process of research and development and subsequent assessment of new health technologies. Patient and public involvement in health technology assessment (HTA) is essential in understanding and assessing wider implications of coverage and reimbursement decisions for patients, their relatives, caregivers, and the general population. There are two approaches to incorporating the patients' voice in HTA, preferably used in a mix. In the first one, patients, caregivers and/or their representatives directly participate at discussions in different stages of the HTA process, often at the same table with other stakeholders. Secondly, patient involvement activities can be supported by evidence on patient value and experience collected directly from patients, caregivers and/or their representatives often by patient groups Patient involvement practices, however, are limited in Central and Eastern European (CEE) countries without clear methodology or regulatory mechanisms to guide patient involvement in the HTA process. This poses the question of transferability of practices used in other countries, and might call for the development of new CEE-specific guidelines and methods. In this study we aim to map potential barriers of patient involvement in HTA in countries of the CEE region.
引用
收藏
页数:9
相关论文
共 73 条
  • [1] Bringing 'the public' into health technology assessment and coverage policy decisions: From principles to practice
    Abelson, Julia
    Giacomini, Mita
    Lehoux, Pascale
    Gauvin, Francois-Pieffe
    [J]. HEALTH POLICY, 2007, 82 (01) : 37 - 50
  • [2] PUBLIC AND PATIENT INVOLVEMENT IN HEALTH TECHNOLOGY ASSESSMENT: A FRAMEWORK FORACTION
    Abelson, Julia
    Wagner, Frank
    DeJean, Deirdre
    Boesveld, Sarah
    Gauvin, Francois-Pierre
    Bean, Sally
    Axler, Renata
    Petersen, Stephen
    Baidoobonso, Shamara
    Pron, Gaylene
    Giacomini, Mita
    Lavis, John
    [J]. INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2016, 32 (04) : 256 - 264
  • [3] Patient value: Perspectives from the advocacy community
    Addario, Bonnie J.
    Fadich, Ana
    Fox, Jesme
    Krebs, Linda
    Maskens, Deborah
    Oliver, Kathy
    Schwartz, Erin
    Spurrier-Bernard, Gilliosa
    Turnham, Timothy
    [J]. HEALTH EXPECTATIONS, 2018, 21 (01) : 57 - 63
  • [4] [Anonymous], PARADIGM EARLY DIALO
  • [5] [Anonymous], SEED PROJECT SHAPING
  • [6] [Anonymous], 2013, Patient and public Involvement Policy
  • [7] [Anonymous], 2019, EUNETHTA GUIDELINES
  • [8] [Anonymous], GUIDELINES STAKEHOLD
  • [9] [Anonymous], 2019, PATIENT INPUT RELATI
  • [10] [Anonymous], PARADIGM